Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9618 posts found.

Takeda reception

Takeda and enGene partner to develop gastro drugs

January 13, 2016 Research and Development Takeda

Takeda is teaming up with Canadian biotech enGene to develop novel therapies for specialty gastrointestinal (GI) diseases, using enGene’s ‘gene …
News
medimmune_logo_on_building

MedImmune and UCSF team up to research RAI treatments

January 13, 2016 Research and Development MedImmune, Precision Medicine, University of California San Francisco, autoimmunity

AstraZeneca’s biologics R&D arm MedImmune and the University of California, San Francisco (UCSF) have announced a new research collaboration focused …
News
MSD logo

MSD to acquire Scottish firm IOmet Pharma

January 12, 2016 Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology

US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
News
a

AstraZeneca and MedImmune in oncology research deals

January 12, 2016 Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics

AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …
News
mark_alles_celgene

Mark Alles is new chief executive of Celgene

January 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Mark Alles

Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at …
Appointment
DMD

The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?

January 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs

The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …
Feature
Roche building

Roche snaps up Tensha Therapeutics for up to $535m

January 12, 2016 Manufacturing and Production, Research and Development Roche, Tensha Therapeutics

Roche has acquired Tensha Therapeutics, a privately-held company based in Cambridge, Massachusetts for up to $535 million.The deal that gives …
News
AbbVie logo

AbbVie tests new hepatitis C drug in Phase III trials

January 11, 2016 Research and Development AbbVie, clinical trials, hepatitis C, phase III

AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …
News

AbbVie begins late stage trials of rheumatoid arthritis drug

January 11, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ABT-494, AbbVie, F-star, JAK-1 inhibitor, rheumatoid arthritis

AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …
News
Elias Zerhouni

Sanofi seals double oncology research deals

January 11, 2016 Research and Development, Sales and Marketing Sanofi, Warp Drive Bio, antibodies, collaboration, immuno-oncology, research

Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …
News
novartis_window

Novartis expands immuno-oncology programme

January 11, 2016 Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology

Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
News
Roche building

Roche presents new data for advanced bladder cancer immunotherapy

January 8, 2016 Medical Communications, Research and Development Roche, atezolizumab, bladder cancer

Roche has announced updated results from a pivotal Phase II study, showing its investigational cancer immunotherapy atezolizumab extended median progression …
News
victoria_photo_feb_14

New head for AI drug discovery firm Molplex

January 7, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Molplex, Victoria Camargo

The artificial intelligence drug discovery company Molplex has appointed Victoria Camargo as its new chief executive. Camargo replaces the co-founder …
Appointment
HIV infected cell

ViiV and Janssen to test new HIV regimen in Phase III trial

January 7, 2016 Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine

Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …
News
dr_paolo_paoletti

PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board

January 7, 2016 Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology

Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …
Appointment
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026